Dr. Ferrer BioPharma Awarded Winner at CPHI Pharmapack 2024 for Groundbreaking GentleMist Technology
The company’s groundbreaking GentleMist Technology received the " Patient-Centric Design " award, highlighting its revolutionary approach in intranasal drug delivery.
- The company’s groundbreaking GentleMist Technology received the " Patient-Centric Design " award, highlighting its revolutionary approach in intranasal drug delivery.
- The GentleMist Technology represents a paradigm shift in the administration of medications as a cutting-edge intranasal drug delivery device that revolutionizes how medications are administered.
- Moving beyond the limitations of traditional nozzles, which causes discomfort, GentleMist Technology utilizes advanced fluid dynamics principles to create a gentler and more effective nasal spray.
- Dr. Ferrer BioPharma holds multiple patents for medications and devices, distinguishing themselves by utilizing their proprietary GentleMist Technology in all their nasal and throat sprays.